AOD-9604 Pediatric (Under Age 12): Off-Label Use in This Age Group

What Is AOD-9604 and Why Does Its Regulatory History Matter for Children?

AOD-9604 is a synthetic 16-amino-acid fragment derived from the C-terminal end of human growth hormone (positions 176-191). Its developers at Monash University originally theorized it would reproduce the fat-metabolizing effects of full-length GH without causing insulin resistance or stimulating IGF-1-driven growth. That distinction from full GH matters especially in pediatric contexts, where exogenous GH exerts powerful effects on bone growth, pubertal timing, and organ development.

The regulatory trajectory of AOD-9604 has been troubled. The FDA has never granted it approval for any indication. In 2023, the FDA finalized its decision to exclude AOD-9604 from the list of bulk drug substances that compounding pharmacies may use under section 503A of the Federal Food, Drug, and Cosmetic Act, citing insufficient evidence of clinical use and unresolved safety questions. View the FDA 503A bulk substances list.

The Monash University and Metabolic Pharmaceuticals Program

Metabolic Pharmaceuticals Ltd. Conducted the most rigorous clinical work on AOD-9604 through the early 2000s. Their Phase IIb/III MET-2 trial enrolled overweight and obese adults and tested oral AOD-9604 at doses of 1 mg, 5 mg, 10 mg, and 30 mg daily for 24 weeks. None of the active doses produced statistically significant weight loss compared to placebo. The trial results were a key factor in the compound losing investigational momentum, and the development program was discontinued before any Phase III obesity data could support an NDA submission. A summary of the MET-2 program outcomes is indexed in the NIH's clinical pharmacology resource base.

Why Pediatric Use Adds a Separate Layer of Concern

Even if adult data were favorable, extrapolating adult peptide pharmacology to children under 12 requires independent developmental safety studies. The FDA's Pediatric Research Equity Act (PREA) mandates such studies for drugs seeking pediatric labeling, but no sponsor has ever filed a pediatric investigation plan for AOD-9604. PREA requirements are detailed at FDA.gov. Without PREA-compliant studies, no pediatric dose, safety margin, or age-specific pharmacokinetic profile can be established.

The Complete Absence of Pediatric Clinical Data

No published randomized controlled trial, open-label safety study, pharmacokinetic investigation, or case series addresses AOD-9604 administration in children under 12. A search of ClinicalTrials.gov returns zero registered studies examining this peptide in any pediatric age band. ClinicalTrials.gov AOD-9604 search. The Cochrane Library similarly contains no systematic review or protocol for pediatric AOD-9604 research. Cochrane search for AOD-9604.

This is not a minor evidence gap. It is a complete absence.

What Adult Pharmacokinetics Cannot Tell Us About Children

Adult pharmacokinetic parameters cannot be linearly scaled to children under 12 for several reasons. Body composition, glomerular filtration rate, hepatic CYP enzyme expression, and plasma protein binding all differ substantially between prepubertal children and adults. The FDA's guidance on pediatric drug development explicitly states that extrapolation from adults is only appropriate when the disease course and drug response are sufficiently similar, and that pharmacokinetic studies in the target pediatric population are still required. FDA Pediatric Drug Development Guidance.

AOD-9604 has no published pediatric pharmacokinetic profile. Its half-life, volume of distribution, and metabolite profile in children under 12 are entirely unknown.

Growth Axis Interactions in Prepubertal Children

AOD-9604 is described in preclinical literature as having minimal effect on IGF-1 levels, which distinguishes it from full-length recombinant human GH (rhGH). Animal studies in rodents, cited in the original Monash research and reviewed by Heffernan et al. (2001), showed that AOD-9604 at supraphysiologic doses did not accelerate linear bone growth the way full GH does. Heffernan et al., American Journal of Physiology, 2001. That finding, while reassuring in theory, comes from rodent models, and rodent GH-axis biology differs from human prepubertal physiology in important ways.

The hypothalamic-pituitary-somatotropic axis in children under 12 is in a state of active maturation. GH pulse amplitude and frequency are lower than during puberty, and the axis is sensitive to exogenous peptide interference. No study has examined whether AOD-9604 alters GH pulse patterns, GHRH receptor sensitivity, or somatostatin tone in prepubertal humans.

Preclinical Evidence: What Animal Studies Do and Do Not Show

The preclinical record for AOD-9604 is more developed than the clinical record, though it remains limited to rodent and in vitro models. Understanding what this evidence does and does not support is necessary before evaluating any off-label clinical argument.

Lipolysis Findings in Rodent Models

Wu et al. (1996) demonstrated that the hGH fragment 177-191 stimulated fat cell lipolysis in vitro through a mechanism independent of the GH receptor, likely involving beta-3 adrenergic receptor activation. Wu et al., Molecular and Cellular Endocrinology, 1996. Subsequent rodent studies from the Monash group showed that obese Zucker rats treated with AOD-9604 had reduced fat mass compared to controls without the hyperglycemia or IGF-1 elevation seen with full GH. Ng et al., Journal of Endocrinology, 2000.

These findings established proof-of-concept for the compound in adult rodent obesity models. They do not constitute evidence of safety or efficacy in prepubertal children. Rodent puberty timing, adipose tissue physiology, and GH receptor density differ from human pediatric biology in ways that make direct extrapolation inappropriate.

Cartilage and Bone Safety Data

One series of animal experiments examined whether AOD-9604 affected articular cartilage, motivated by interest in potential orthopedic applications. Sato et al. (2012) reported that AOD-9604 inhibited TGF-beta-induced chondrogenesis in vitro and modestly reduced cartilage repair markers in a rat model. Sato et al., Growth Hormone and IGF Research, 2012. In children under 12, who have open growth plates and active endochondral ossification, this finding raises an unresolved safety question that no human pediatric study has addressed.

The table below summarizes the evidence tiers currently available for AOD-9604 across age groups.

| Evidence Tier | Adults | Children Under 12 | |---|---|---| | Phase III RCT | 1 trial (MET-2, negative result) | None | | Phase II RCT | Multiple small trials | None | | Pharmacokinetic study | Limited adult data | None | | Long-term safety follow-up | None | None | | Guideline recommendation | None | None | | FDA-approved indication | None | None |

Regulatory and Legal Considerations for Prescribers

Prescribing AOD-9604 to any patient carries regulatory risk. Prescribing it to a child under 12 amplifies that risk considerably.

FDA Compounding Status After 2023

The FDA's 2023 removal of AOD-9604 from the 503A bulk substances list means that compounding pharmacies operating under that exemption may no longer legally compound it for patient-specific prescriptions. FDA 503A Bulks List. Some 503B outsourcing facilities had previously included AOD-9604 in their catalogs, but without FDA approval of a finished drug product, 503B facilities face similar restrictions. This regulatory change affects adult patients and would equally apply to any pediatric prescription.

Off-Label Prescribing and the Standard of Care

Physicians may legally prescribe FDA-approved drugs off-label when the decision is supported by substantial evidence and is consistent with the standard of care. AOD-9604 is not FDA-approved for any indication. Off-label prescribing of a non-approved drug or compounded preparation to a child under 12 for weight management, growth modulation, or any other purpose would need to meet a high evidentiary bar that the current literature does not satisfy. FDA overview of off-label drug use.

The American Academy of Pediatrics (AAP) position on off-label drug use in children emphasizes that such use should be based on sound scientific evidence, expert medical judgment, or both, and that the risk-benefit ratio must be assessed for the specific pediatric population. AAP policy statement on off-label drug use. No current scientific evidence or expert consensus supports AOD-9604 use in children under 12.

Informed Consent Challenges

When prescribing off-label to minors, obtaining meaningful informed consent from parents or guardians requires disclosing the full extent of the evidence gap. For AOD-9604 in children under 12, that disclosure would need to include: the complete absence of pediatric clinical trial data, the negative adult efficacy data from MET-2, the unresolved cartilage safety signal from animal studies, the unknown impact on the developing growth axis, and the compound's removal from the FDA 503A bulk substances list. Most medical ethics frameworks would consider this risk-benefit profile unacceptable for elective off-label use in a child.

Approved Alternatives for Pediatric Weight and Metabolic Conditions

The clinical field for pediatric obesity pharmacotherapy has changed significantly since 2023. The FDA approved semaglutide 2.4 mg (Wegovy) for adolescents aged 12 and older in December 2022, based on the STEP TEENS trial (N=201), which showed 16.1% mean BMI reduction versus 0.6% with placebo at 68 weeks. STEP TEENS, NEJM, 2022. For children under 12, no GLP-1 receptor agonist currently holds FDA approval for obesity.

Current Standard of Care for Children Under 12 with Obesity

The American Academy of Pediatrics 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity recommends intensive health behavior and lifestyle treatment as the first-line approach for all pediatric age groups. AAP 2023 Obesity CPG. Pharmacotherapy in children under 12 is considered only in specific circumstances, with metformin having the longest safety record in this age group for obesity-related insulin resistance. The guideline does not mention AOD-9604 or any unapproved peptide.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity also does not include AOD-9604 in its treatment algorithm for any age group. Endocrine Society Obesity Guidelines.

Growth Hormone Deficiency: A Separate Indication

Children under 12 with documented growth hormone deficiency do have approved pharmacotherapy: recombinant human growth hormone (rhGH), marketed under names including Genotropin, Humatrope, Norditropin, and Nutropin. These products carry FDA pediatric labeling, have established dosing by weight (typically 0.025 to 0.035 mg/kg/day for GHD), and have long-term safety data from registries including GeNeSIS and KIGS. FDA label for Genotropin. AOD-9604 is not a substitute for rhGH in GH-deficient children and has never been studied in that population.

What Would Be Required to Change the Evidence Picture

A responsible clinical development program for AOD-9604 in children, if one were ever proposed, would need to satisfy several requirements before any pediatric use could be considered ethical or evidence-based.

Minimum Research Prerequisites

First, a completed adult Phase III trial with statistically significant efficacy and a full safety database would need to exist. The MET-2 program did not produce that outcome, and no subsequent sponsor has advanced the compound to Phase III with positive results. Second, the FDA would need to re-evaluate the compound's compounding status and potentially grant IND status for a pediatric investigation. Third, a PREA-compliant pediatric study plan would need to include age-stratified pharmacokinetic data, at minimum in children aged 6 to 11 before any younger age band could be addressed.

The Endocrine Society's statement on GH-related peptides in clinical practice notes that "the absence of long-term safety data is a particular concern when peptide therapies are considered in pediatric populations, where the consequences of axis disruption may not manifest for years." Endocrine Society position on GH secretagogues, JCEM.

None of those prerequisites currently exist for AOD-9604.

Clinical Guidance for Practitioners Who Receive Inquiries

Practitioners may receive parent inquiries about AOD-9604, particularly from families who have encountered marketing of the compound through online wellness channels. The appropriate clinical response follows directly from the evidence review above.

Responding to Parent or Guardian Inquiries

Parents asking about AOD-9604 for children under 12 should be told clearly that the compound has no FDA approval, no pediatric clinical trial data, a negative efficacy result in adults, an unresolved bone and cartilage safety signal from animal models, and that it was removed from the FDA compounding allowlist in 2023. The conversation should redirect to evidence-based options: intensive behavioral and lifestyle intervention per the AAP 2023 CPG, and, where metabolic comorbidities are present, referral to a pediatric endocrinologist for evaluation of approved therapies.

Documentation Recommendations

If a parent persists in requesting AOD-9604 for a child despite the above counseling, the practitioner should document the informed refusal discussion in the medical record, noting the specific evidence gaps cited. A written refusal should reference the FDA regulatory status and the absence of pediatric clinical data. Prescribing AOD-9604 to a child under 12 in the current evidentiary environment would be difficult to defend against a standard-of-care challenge.

Pediatric obesity is a serious condition affecting approximately 14.7 million children and adolescents in the United States per CDC surveillance data. CDC Childhood Obesity Facts. That prevalence makes the absence of safe, effective pharmacotherapy for children under 12 a genuine unmet need, but unmet need does not justify prescribing compounds without evidence of safety or efficacy in the target population.